0 CHECKOUT

Emergent BioSolutions Inc. - Product Pipeline Review - 2015

  • ID: 3280647
  • May 2015
  • 65 pages
  • Global Markets Direct
1 of 3

Emergent BioSolutions Inc. - Product Pipeline Review - 2015

Summary

This, ‘Emergent BioSolutions Inc. - Product Pipeline Review - 2015’, provides an overview of the Emergent BioSolutions Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Emergent BioSolutions Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation READ MORE >

Note: Product cover images may vary from those shown
2 of 3

List of Tables
List of Figures
Emergent BioSolutions Inc. Snapshot
Emergent BioSolutions Inc. Overview
Key Information
Key Facts
Emergent BioSolutions Inc. - Research and Development Overview
Key Therapeutic Areas
Emergent BioSolutions Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Emergent BioSolutions Inc. - Pipeline Products Glance
Emergent BioSolutions Inc. - Late Stage Pipeline Products
Filing rejected/Withdrawn Products/Combination Treatment Modalities
Emergent BioSolutions Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Emergent BioSolutions Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Emergent BioSolutions Inc. - Drug Profiles
coagulation factor IX (recombinant)
Product Description
Mechanism of Action
R&D Progress
AV-7909
Product Description
Mechanism of Action
R&D Progress
otlertuzumab
Product Description
Mechanism of Action
R&D Progress
PreviThrax
Product Description
Mechanism of Action
R&D Progress
AVP-21D9
Product Description
Mechanism of Action
R&D Progress
ES-414
Product Description
Mechanism of Action
R&D Progress
antihemophilic factor (recombinant)
Product Description
Mechanism of Action
R&D Progress
ES-210
Product Description
Mechanism of Action
R&D Progress
ES-301
Product Description
Mechanism of Action
R&D Progress
ES-306
Product Description
Mechanism of Action
R&D Progress
EV-035
Product Description
Mechanism of Action
R&D Progress
GC-072
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit Hemagglutinin for Influenza
Product Description
Mechanism of Action
R&D Progress
MVA-RSV
Product Description
Mechanism of Action
R&D Progress
MVAH-5HA
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein Cytotoxic to Cells Expressing CD19 and CD3 for Cancer
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Target HER-2 and CD3 for Cancer
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Target RON and CD3 for Cancer
Product Description
Mechanism of Action
R&D Progress
Vaccines for Undisclosed Indication
Product Description
Mechanism of Action
R&D Progress
Emergent BioSolutions Inc. - Pipeline Analysis
Emergent BioSolutions Inc. - Pipeline Products by Target
Emergent BioSolutions Inc. - Pipeline Products by Route of Administration
Emergent BioSolutions Inc. - Pipeline Products by Molecule Type
Emergent BioSolutions Inc. - Pipeline Products by Mechanism of Action
Emergent BioSolutions Inc. - Recent Pipeline Updates
Emergent BioSolutions Inc. - Dormant Projects
Emergent BioSolutions Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Anthrivig
Immune Globulin
Leucotropin
PEP-35
TST-10088
Emergent BioSolutions Inc. - Company Statement
Emergent BioSolutions Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Emergent BioSolutions Inc., Key Information
Emergent BioSolutions Inc., Key Facts
Emergent BioSolutions Inc. - Pipeline by Indication, 2015
Emergent BioSolutions Inc. - Pipeline by Stage of Development, 2015
Emergent BioSolutions Inc. - Monotherapy Products in Pipeline, 2015
Emergent BioSolutions Inc. - Partnered Products in Pipeline, 2015
Emergent BioSolutions Inc. - Partnered Products/ Combination Treatment Modalities, 2015
Emergent BioSolutions Inc. - Filing rejected/Withdrawn, 2015
Emergent BioSolutions Inc. - Phase II, 2015
Emergent BioSolutions Inc. - Phase I, 2015
Emergent BioSolutions Inc. - Preclinical, 2015
Emergent BioSolutions Inc. - Discovery, 2015
Emergent BioSolutions Inc. - Pipeline by Target, 2015
Emergent BioSolutions Inc. - Pipeline by Route of Administration, 2015
Emergent BioSolutions Inc. - Pipeline by Molecule Type, 2015
Emergent BioSolutions Inc. - Pipeline Products by Mechanism of Action, 2015
Emergent BioSolutions Inc. - Recent Pipeline Updates, 2015
Emergent BioSolutions Inc. - Dormant Developmental Projects,2015
Emergent BioSolutions Inc. - Discontinued Pipeline Products, 2015
Emergent BioSolutions Inc., Other Locations
Emergent BioSolutions Inc., Subsidiaries

List of Figures
Emergent BioSolutions Inc. - Pipeline by Top 10 Indication, 2015
Emergent BioSolutions Inc. - Pipeline by Stage of Development, 2015
Emergent BioSolutions Inc. - Monotherapy Products in Pipeline, 2015
Emergent BioSolutions Inc. - Pipeline by Top 10 Target, 2015
Emergent BioSolutions Inc. - Pipeline by Top 10 Route of Administration, 2015
Emergent BioSolutions Inc. - Pipeline by Top 10 Molecule Type, 2015
Emergent BioSolutions Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.